oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 24 )

2018 ( 184 )

2017 ( 176 )

2016 ( 177 )

Custom range...

Search Results: 1 - 10 of 15484 matches for " Chao-Hung Kuo "
All listed articles are free for downloading (OA Articles)
Page 1 /15484
Display every page Item
Effects of natto extract on endothelial injury in a rat model
Chang,Chin-Hsien,Chen,Kuo-Ti,Lee,Tsong-Hai,Wang,Chao-Hung
Acta Medica Okayama , 2010,
Abstract: Vascular endothelial damage has been found to be associated with thrombus formation, which is considered to be a risk factor for cardiovascular disease. A diet of natto leads to a low prevalence of cardiovascular disease. The aim of the present study was to investigate the effects of natto extract on vascular endothelia damage with exposure to laser irradiation. Endothelial damage both in vitro and in vivo was induced by irradiation of rose bengal using a DPSS green laser. Cell viability was determined by MTS assay, and the intimal thickening was verified by a histological approach. The antioxidant content of natto extract was determined for the free radical scavenging activity. Endothelial cells were injured in the presence of rose bengal irradiated in a dose-dependent manner. Natto extract exhibits high levels of antioxidant activity compared with purified natto kinase. Apoptosis of laser-injured endothelial cells was significantly reduced in the presence of natto extract. Both the natto extract and natto kinase suppressed intimal thickening in rats with endothelial injury. The present findings suggest that natto extract suppresses vessel thickening as a synergic effect attributed to its antioxidant and anti-apoptosis properties.
The Diagnostic Value of Computed Tomographic Coronary Angiography in Patients with Acute Myocardial Infarction versus Stable Angina Pectoris: A Preliminary Report
Shih-Jen Chen,Li-Tang Kuo,Chao-Hung Wang,Wen-Jin Cherng
Chang Gung Medical Journal , 2011,
Abstract: Background: Computed tomographic coronary angiography (CTA) is a non-invasive alternative to conventional coronary angiography (CCA) in detecting chroniccoronary artery disease (CAD). However, the value of CTA in estimatingacute myocardial infarction (AMI) has not been evaluated.Methods: CTA and CCA were performed on 10 patients with non-ST-elevated AMIand 17 patients with stable angina pectoris. The plaque components andstenosis severity were assessed by both modalities to clarify the diagnosticvalues of CTA in AMI and stable angina pectoris.Results: A high total coronary artery calcium (CAC) score was significantly correlated with the presence of CAD and the target lesion CAC score (p < 0.01). TheAMI group tended to have a lower target CAC score (p = 0.10) and targetplaque burden (p = 0.27), compared to the stable angina pectoris group. Toestimate the coronary artery stenotic severity, CTA and CCA had concordantcorrelations in all segments, except in the proximal left anterior descending(LAD) artery. The calcium score and calcification fraction percentage in theproximal LAD artery were significantly higher than those of other segments(p < 0.01). Compared to CCA, CTA overestimated the severity of stenosis inthe proximal LAD arterial segment in the stable angina pectoris group (p =0.028), but not in the AMI group.Conclusions: CTA has diagnostic values similar to those of CCA in detecting coronarylesions in patients with AMI or stable angina pectoris. However, a high levelof plaque CAC in the stable angina pectoris group may lead to an overestimation of the severity of coronary stenosis, especially in the proximal LADarterial segment. Although less remarkable, the impact of CAC on the diagnostic value of CTA was still substantial in patients with AMI.
Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection
Chao-Hung Hung, Jing-Houng Wang, Tsung-Hui Hu, Chien-Hung Chen, Kuo-Chin Chang, Yi-Hao Yen, Yuan-Hung Kuo, Ming-Chao Tsai, Sheng-Nan Lu, Chuan-Mo Lee
World Journal of Gastroenterology , 2010,
Abstract: AIM: To elucidate the role of insulin resistance (IR) and serum adiponectin level in hepatocellular carcinoma (HCC) associated with chronic hepatitis C.METHODS: Clinical and biochemical characteristics were collected from 165 consecutive patients with newly diagnosed HCC. Homeostasis model assessment of IR (HOMA-IR) and serum adiponectin level were investigated in 188 patients with different stages of hepatitis C virus (HCV) infection.RESULTS: Among HCC patients, type 2 diabetics (DM) was more prevalent in HCV subjects (35.6%, n = 59) compared to hepatitis B virus (HBV; 12.7%, n = 63) or non-HBV, non-HCV cases (7.1%, n = 28). In patients with chronic hepatitis C, HCC subjects had higher blood sugar (P < 0.001), insulin level (P = 0.003) and HOMA-IR (P = 0.018) than those with chronic hepatitis and advanced fibrosis. Age, male sex and body mass index were significantly associated with serum adiponectin level, whereas HOMA-IR was not. Based on stepwise logistic regression analysis, age (OR: 1.124, P < 0.001), serum insulin level (OR: 1.585, P < 0.001), HOMA-IR (OR: 0.495, P = 0.001), DM (OR: 11.601, P = 0.002) and male sex (OR: 3.877, P = 0.016) were independently associated with HCC. This result was similar even if the diabetic subjects were excluded for analysis.CONCLUSION: Insulin resistance measured by HOMA-IR, regardless of the presence of diabetes, is significantly associated with HCC development in patients with chronic HCV infection.
The Changes of Liver Stiffness and Its Associated Factors for Chronic Hepatitis B Patients with Entecavir Therapy
Yuan-Hung Kuo, Sheng-Nan Lu, Chien-Hung Chen, Kuo-Chin Chang, Chao-Hung Hung, Wei-Chen Tai, Ming-Chao Tsai, Po-Lin Tseng, Tsung-Hui Hu, Jing-Houng Wang
PLOS ONE , 2014, DOI: 10.1371/journal.pone.0093160
Abstract: Liver stiffness measurement (LSM) using transient elastography has been proposed to assess liver fibrosis well in various liver diseases. This study was to determine the changes of LSM and its associated factors for chronic hepatitis B (CHB) patients undergoing Entecavir therapy. Consecutive CHB patients underwent Entecavir therapy with two LSMs were enrolled. Patients with aspartate transaminase (AST) and/or alanine transaminase ≧200 IU/L were excluded. The retrospective study enrolled 233 patients including 132 without cirrhosis (group 1) and 101 with cirrhosis (group 2). The mean values of initial liver stiffness were 7.9 and 16.6 kPa for patients in group 1 and group 2, respectively (p<0.001). In addition to the decline of transaminase levels, there was significant reduction of liver stiffness value in a mean interval of 52.8 and 61.9 weeks between the two LSMs for patients in group 1 and 2, respectively (p<0.001). Multivariate analysis showed that higher initial LSM value and presence of hepatitis B e-antigen were associated with a greater decline of LSM value, whereas follow-up AST≧40 IU/L with increased LSM value for group 1 patients. For group 2 patients, longer interval between the two LSMs, higher initial LSM value and AST≧40 IU/L were associated with a greater decline of LSM value, whereas presence of diabetes mellitus (DM) contributed to increased LSM value. In conclusion, CHB patients improved their LSM values after Entecavir therapy. Higher initial LSM value contributed to greater LSM reduction. However, in cirrhotic patients, DM was associated with an increased LSM value after therapy.
Current Pharmacological Management of Gastroesophageal Reflux Disease
Yao-Kuang Wang,Wen-Hung Hsu,Sophie S. W. Wang,Chien-Yu Lu,Fu-Chen Kuo,Yu-Chung Su,Sheau-Fang Yang,Chiao-Yun Chen,Deng-Chyang Wu,Chao-Hung Kuo
Gastroenterology Research and Practice , 2013, DOI: 10.1155/2013/983653
Abstract: Gastroesophageal reflux disease (GERD), a common disorder with troublesome symptoms caused by reflux of gastric contents into the esophagus, has adverse impact on quality of life. A variety of medications have been used in GERD treatment, and acid suppression therapy is the mainstay of treatment for GERD. Although proton pump inhibitor is the most potent acid suppressant and provides good efficacy in esophagitis healing and symptom relief, about one-third of patients with GERD still have persistent symptoms with poor response to standard dose PPI. Antacids, alginate, histamine type-2 receptor antagonists, and prokinetic agents are usually used as add-on therapy to PPI in clinical practice. Development of novel therapeutic agents has focused on the underlying mechanisms of GERD, such as transient lower esophageal sphincter relaxation, motility disorder, mucosal protection, and esophageal hypersensitivity. Newer formulations of PPI with faster and longer duration of action and potassium-competitive acid blocker, a newer acid suppressant, have also been investigated in clinical trials. In this review, we summarize the current and developing therapeutic agents for GERD treatment. 1. Introduction Gastroesophageal reflux disease (GERD) is a common gastrointestinal disorder in the general population, and its prevalence is increasing worldwide [1]. According to the Montreal definition, GERD is diagnosed when the reflux of stomach contents causes troublesome symptoms and/or complications [2], and it is the most common outpatient gastrointestinal disease diagnosed in USA [3]. Reflux from stomach causes symptoms like heartburn and regurgitation, which are the cardinal symptoms of GERD, and other symptoms, such as chest pain, asthma, hoarseness, and sleep disturbance, are also considered as atypical or extraesophageal symptoms of GERD [4]. Troublesome symptoms of GERD have adverse impact on health-related quality of life (HRQL) [5], and patients with more frequent or more severe symptoms have lower HRQL, work productivity, and sleep quality [5, 6]. Chronic reflux is also an important risk factor of esophageal adenocarcinoma [7]. There are many factors contributing to GERD, including transient lower esophageal sphincter relaxation (TLESR), reduced LES pressure, impaired esophageal mucosal defense, poor esophageal clearance, visceral hypersensitivity, hiatal hernia, and delayed gastric emptying, and TLESRs is the predominant mechanism of reflux formation [8]. Obesity is an independent risk factor for development of GERD and is also associated with its complications,
The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012
Chao-Hung Kuo,Fu-Chen Kuo,Huang-Ming Hu,Chung-Jung Liu,Sophie S. W. Wang,Yen-Hsu Chen,Ming-Chia Hsieh,Ming-Feng Hou,Deng-Chyang Wu
Gastroenterology Research and Practice , 2012, DOI: 10.1155/2012/168361
Abstract: This paper reviews the literature about first-line therapies for H. pylori infection in recent years. First-line therapies are facing a challenge because of increasing treatment failure due to elevated antibiotics resistance. Several new treatment strategies that recently emerged to overcome antibiotic resistance have been surveyed. Alternative first-line therapies include bismuth-containing quadruple therapy, sequential therapy, concomitant therapy, and hybrid therapy. Levofloxacin-based therapy shows impressive efficacy but might be employed as rescue treatment due to rapidly raising resistance. Rifabutin-based therapy is also regarded as a rescue therapy. Several factors including antibiotics resistance, patient compliance, and CYP 2C19 genotypes could influence the outcome. Clinicians should use antibiotics according to local reports. It is recommended that triple therapy should not be used in areas with high clarithromycin resistance or dual clarithromycin and metronidazole resistance. 1. Introduction Eradicating Helicobacter pylori (H. pylori) is the most important aspect of managing H. pylori-related gastrointestinal diseases. In the past decade, the Maastricht III Consensus Report has recommended that proton pump inhibitor- (PPI-) clarithromycin-amoxicillin or metronidazole treatment is the first choice for H. pylori infection [1]. Although some studies have revealed that the eradication rates of standard triple therapies are around 80% (by per-protocol (PP) analysis) [2, 3], most studies have demonstrated the success rate of recommended triple therapies is falling [4–7]. According to recent studies, such eradication rates have plummeted to even 25%–60% [8–10]. The many causes of fall in efficacy are varied including antibiotic resistance, poor compliance, high gastric acidity, high bacterial load, and the cytochrome P450 2C19 (CYP2C19) polymorphism [10]. Compliance is an important factor where patients with good compliance (taking more than 60% of prescribed agents) have a higher treatment success compared to patients with poor compliance (96 versus 69%) [11]. The factors that negatively affect successful eradication are an increase in body mass index and smoking [12, 13]. Besides, other factors including the patient’s history of antibiotic use, the cost, and availability of the drugs would also influence the choice of regimen. In order to overcome the challenge of decreasing eradication rates, many novel first-line therapies have been developed. According to guidelines of the Maastricht III, the minimal acceptable eradication level recommended
Association between Helicobacter pylori seropositivity and digestive tract cancers
I-Chen Wu, Deng-Chyang Wu, Fang-Jung Yu, Jaw-Yuan Wang, Chao-Hung Kuo, Sheau-Fang Yang, Chao-Ling Wang, Ming-Tsang Wu
World Journal of Gastroenterology , 2009,
Abstract: AIM: To explore the role of Helicobacter pylori (H pylori) infection on the risk of digestive tract cancers.METHODS: In total, 199 oral squamous-cell carcinoma (SCC), 317 esophageal SCC, 196 gastric cardia and non-cardia adenocarcinoma and 240 colon adenocarcinoma patients were recruited for serum tests of H pylori infection. Two hospital- and one community-based control groups were used for the comparisons. H pylori seropositivity was determined by an enzyme linked immunosorbent assay method against H pylori IgG.RESULTS: Presence of H pylori infection was significantly inversely associated with esophageal SCC [adjusted odds ratio (AOR): 0.315-0.472, all P-value < 0.05] but positively associated with gastric adenocarcinoma (both cardia and non-cardia) (AOR: 1.636-3.060, all P-value < 0.05) in comparison to the three control groups. Similar results were not found in cancers of the oral cavity and colon.CONCLUSION: Our findings support the finding that H pylori seropositivity is inversely associated with esophageal SCC risk, but increases the risk of gastric cardia adenocarcinoma.
Attenuated Cardiac Mitochondrial-Dependent Apoptotic Effects by Li-Fu Formula in Hamsters Fed with a Hypercholesterol Diet
Wei-Wen Kuo,Tsai-Ching Hsu,Mei-Haung Chain,Chao-Hung Lai,Wen-Hong Wang,Fuu-Jen Tsai,Chang-Hai Tsai,Chieh-His Wu,Chih-Yang Huang,Bor-Show Tzang
Evidence-Based Complementary and Alternative Medicine , 2011, DOI: 10.1093/ecam/nep182
Abstract: Apoptosis involves in the pathogenesis of various cardiac abnormalities. This study intends to evaluate the effects of Li-Fu formula on cardiac apoptosis induced by hyper-cholesterol diet. Twenty-four male Golden Syrian hamsters were randomly divided into Control, Cholesterol and Li-Fu formula groups. Histopathological analysis, western blotting and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays were performed to measure the effects of Li-Fu formula on left ventricle. Significantly reduced TUNEL-positive cells and mitochondria- dependent apoptosis were observed in the left ventricle of hamsters from Li-Fu formula group compared to the Cholesterol group. Additionally, induced cardiac insulin like growth factor I receptor (IGFIR)-dependent survival pathway was detected in the Li-Fu formula group compared to the Cholesterol group. Besides, minor fibrosis, increased collagen deposition, and myofibril disarray was detected in the Cholesterol group, whereas the reductions of collagen deposition and myofibril disarray were observed in the Li-Fu formula group. This study demonstrated that Li-Fu formula not only reduced the mitochondria-dependent apoptosis and fibrosis, but also enhanced the IGF-I survival pathway in the left ventricle from high cholesterol-fed hamsters. We suggest the protective effects of Li-Fu formula on cardiac apoptosis and therapeutic potentials against cardiovascular disease.
Preoperative serum carcinoembryonic antigen, albumin and age are supplementary to UICC staging systems in predicting survival for colorectal cancer patients undergoing surgical treatment
Li-Chu Sun, Koung-Shing Chu, Su-Chen Cheng, Chien-Yu Lu, Chao-Hung Kuo, Jan-Sing Hsieh, Ying-Ling Shih, Shun-Jen Chang, Jaw-Yuan Wang
BMC Cancer , 2009, DOI: 10.1186/1471-2407-9-288
Abstract: Between January 1996 and December 2006, a total of 1367 CRC patients who underwent surgical treatment in Kaohsiung Medical University Hospital were analyzed. We retrospectively investigated clinicopathologic features of these patients. All patients were followed up intensively, and their outcomes were investigated completely.Of 1367 CRC patients, there were seven hundred and fifty-seven males (55.4%) and 610 (44.6%) females. The median follow-up period was 60 months (range, 3–132 months). A multivariate analysis identified that low serum albumin level (P = 0.011), advanced UICC stage (P < 0.001), and high carcinoembryonic antigen (CEA) level (P < 0.001) were independent prognostic factors of cancer-specific survival. Meanwhile, a multivariate analysis showed age over 65 years (P < 0.001), advanced UICC stage (P < 0.001), and high CEA level (P < 0.001) were independent prognostic factors of overall survival. Furthermore, combination of UICC stage, serum CEA and albumin levels as predictors of cancer-specific survival showed that the poorer the prognostic factors involved, the poorer the cancer-specific survival rate. Likewise, combination of UICC stage, age and serum CEA level as predictors of overall survival showed that the poorer the prognostic factors involved, the poorer the overall survival rate. Of these prognostic factors, preoperative serum CEA level was the only significant prognostic factor for patients with stage II and III CRCs in both cancer-specific and overall survival categories.Preoperative serum albumin level, CEA level and age could prominently affect postoperative outcome of CRC patients undergoing surgical treatment. In addition to conventional UICC staging system, it might be imperative to take these additional characteristics of factors into account in CRC patients prior to surgical treatment.Colorectal cancer (CRC) is the most common cancer and also the third leading cause of cancer death in Taiwan, and it is also a significant health problem
Short-term Celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model
Chao-Hung Kuo, Huang-Ming Hu, Pei-Yun Tsai, I-Chen Wu, Sheau-Fang Yang, Lin-Li Chang, Jaw-Yuan Wang, Chang-Ming Jan, Wen-Ming Wang, Deng-Chyang Wu
World Journal of Gastroenterology , 2009,
Abstract: AIM: To evaluate the optimal intervention point of a selective cyclooxygenase-2 (COX-2) inhibitor, Celecoxib, for inhibiting Helicobacter pylori (H pylori)-associated gastric carcinogenesis in Mongolian gerbils (MGs).METHODS: One hundred and twelve MGs were divided into six groups (A-F). One hundred gerbils were inoculated with H pylori (groups A-E). Twelve gerbils were inoculated with vehicle broth only (group F). After 4 wk, they were given N’-methyl-N’-nitro-N-nitroso-guanidine (MNNG) (50 μg/mL) in the drinking water for 20 wk. In groups B-E, the animals were given the stock Celecoxib (10 mg/kg per day) diet from the 21st, 31st, 21st and 41st week respectively. The periods of administering Celecoxib were 30, 20, 20, and 15 wk respectively. On the 51st week, the animals were sacrificed for histological examination. Local PCNA expression was examined by the immunohistochemistry method. The expression of COX-2 protein was assessed by Western Blot. Analysis used the χ2 test. The difference was regarded as significant when P value was less than 0.05.RESULTS: Seventeen percent (17/100) of H pylori-infected MGs developed gastric cancer. All of these lesions were well-differentiated adenocarcinoma. The incidence rates of adenocarcinoma in groups A-F were 40%, 0%, 0%, 20%, 25%, and 0% respectively. The inflammatory scores were higher in group B than in other groups. There was no inflammatory response noted in group F. Celecoxib treatment resulted in a significant reduction in the proliferation of H pylori-infected mucosal cells (groups B, C and D) (P < 0.01).The expression of COX-2 protein was significantly attenuated in the groups which were Celecoxib-treated for more than 20 wk (groups B, C, D). The groups treated with Celecoxib had a significantly lower rate of advanced gastric cancer (34% vs 75%, P < 0.001) There were no sudden deaths in any of the groups.CONCLUSION: Short-term treatment with Celecoxib has an anti-carcinogenic effect, and resulted in less severe inflammation and inhibited the invasive degree of gastric cancer.
Page 1 /15484
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.